MEDICALE CORP. 10-K

 false 2024 FY 0001827855 0 0 0 0 0

 2024-03-31

 2025-01-13

 2024-07-01

 2022-10-01

 2022-09-30

 2022-09-30

 2022-09-30

 2022-09-30

 2022-10-01

 2022-10-01

 2022-10-01

 2022-01-01
 2022-12-28

 MCLE:AlboroviMember

 MCLE:AlboroviMember

 MCLE:ZuMember

 MCLE:ZuMember

 MCLE:ConvertibleNote1Member

 2023-12-31

 MCLE:ConvertibleNote1Member

 2023-12-31

 MCLE:ConvertibleNote1Member

 MCLE:ConvertibleNote2Member

 2024-03-31

 MCLE:ConvertibleNote2Member

 2024-03-31

 MCLE:ConvertibleNote2Member

 MCLE:ConvertibleNote3Member

 2024-06-30

 MCLE:ConvertibleNote3Member

 2024-06-30

 MCLE:ConvertibleNote3Member

 MCLE:ConvertibleNote4Member

 MCLE:ConvertibleNote4Member

 U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 Form 10-K

 Mark One

 ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended September 30, 2024

 TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from ______ to _______

 Commission File No. 333-250025

 (Exact name of registrant as specified in its charter)

 Nevada

 (State or Other Jurisdiction of

 Incorporation or Organization)

 8000

 (Primary Standard Industrial

 Classification Number)

 EIN 98-1556944

 (IRS Employer

 Identification Number)

 9314 Forest Hill Blvd #929

 Wellington, FL 33411

 ( 407) 245-7339

 medicalecorp@yahoo.com

 (Address, including zip code, and telephone number,

 including area code, of registrant's principal
executive offices)

 Incorp Services, Inc

 3773 Howard Hughes Parkway Suite 500 S

 Las Vegas, NV 89169-6014

 +1 (702) 866-2500

 (Name, address, including zip code, and telephone
number,

 including area code, of agent for service)

 Securities registered pursuant to Section 12(b)
of the Act:

 Title of each class

 Name of each exchange on which registered

 N/A

 N/A

 Securities registered pursuant to section 12(g) of the Act: None

 Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No.

 Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

 Indicate by checkmark whether the issuer: (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
 No

 Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes No

 Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"and
"emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.

 Indicate by check mark whether the registrant
has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by checkmark whether the registrant is
a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 As of March 31, 2024 the last business day
of the registrant's most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting
common equity held by non-affiliates was $ 0.

 Class

 Outstanding as of January 13, 2025

 Common Stock: $0.0001

 PART 1

 ITEM 1

 Description of Business

 ITEM 1A

 Risk Factors

 ITEM 1B

 Unresolved Staff Comments

 ITEM 1C

 Cybersecurity

 ITEM 2

 Properties

 ITEM 3

 Legal Proceedings

 ITEM 4

 Mine Safety Disclosures

 ITEM 5

 Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

 ITEM 6

 [Reserved]

 ITEM 7

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 ITEM 7A

 Quantitative and Qualitative Disclosures about Market Risk

 ITEM 8

 Financial Statements and Supplementary Data

 ITEM 9

 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

 ITEM 9A

 Controls and Procedures

 ITEM 9B

 Other Information

 ITEM 9C

 Disclosure Regarding foreign Jurisdictions that Prevent Inspections

 ITEM 10

 Directors, Executive Officers, Promoters and Control Persons of the Company

 ITEM 11

 Executive Compensation

 ITEM 12

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 ITEM 13

 Certain Relationships and Related Transactions

 ITEM 14

 Principal Accountant Fees and Services

 ITEM 15

 Exhibits

 ITEM 16

 Form 10-K Summary

 i

 FORWARD-LOOKING STATEMENTS

 This annual report contains forward-looking statements.
These statements relate to future events or our future financial performance. These statements often can be identified by the use of terms
such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate"
or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such
statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the
date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking
statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to
differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation
subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect
the occurrence of anticipated or unanticipated events.

 ii

 Item 1. Description of Business

 GENERAL INFORMATION ABOUT OUR COMPANY

 Medicale Corp ("we," "our"
or the "Company") was incorporated in the State of Nevada on August 17, 2020. To date we have not generated revenue from our
business operations. Furthermore, as we are still in the early stages of developing our business and expect to operate at a loss as we
grow our business. There is little historical financial information about our Company upon which to base an evaluation of our performance
or to make a decision regarding an investment in our shares. We cannot guarantee that we will be successful in our business operations
or that we will achieve significant, if any, level of market acceptance for our proposed business operations and products. Our business
could be subject to any or all of the problems, expenses, delays and risks inherent in the establishment of a new business enterprise,
including limited capital resources, possible changes in consumer interest, possible cost overruns due to price and cost increases in
services or products we require.

 We have never been subject to any bankruptcy proceedings.
The principal place of business is now located at 9314 Forest Hill Blvd #929, Wellington, FL 33411. Our telephone number is (407)245-7339.

 As of the date of this report, the Company had
not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital,
and continuing the Company's public reporting.

 Item 1A. Risk Factors.

 Not required for Smaller reporting companies.

 Item 1B. Unresolved Staff Comments.

 Not required for Smaller reporting companies.

 Item 1C. Cybersecurity

 Risk Management and Strategy

 Currently, the only cybersecurity risk is from
the use of websites associated with the Company. All hosting and hosting related services of these websites are engaged via reputable
companies such as Namecheap, Godaddy and Cloudflare.

 These aforementioned companies utilize the latest
industrial standards for security and data protection. Safeguards include continuous server monitoring, server and infrastructure security
configuration consistently applied across all servers, firewall protection, anti-malware protection, a dedicated internal security team,
applied Open Worldwide Application Security Project secure coding practices, and regular data backups.

 Item 2. Properties.

 Currently we don't own any properties. Our
business office is located at 9314 Forest Hill Blvd #929, Wellington, FL 33411.

 Item 3. Legal Proceedings.

 We are not currently a party to any legal proceedings,
and we are not aware of any pending or potential legal actions.

 Item 4. Mine Safety Disclosures.

 Not Applicable.

 Item 5. Market for Registrant's Common
Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities.

 The company stock is not trading at the moment.

 Registered Holders of our Common Stock

 As of September 30, 2024, there were approximately
32 record owners of our common stock including director.

 Dividends

 The Company has never declared or paid cash dividends
on its common stock and does not anticipate paying cash dividends in the foreseeable future.

 Recent Sales of Unregistered Securities

 During our fiscal years ended September 30,
2024 and 2023, we had no sales of unregistered shares.

 Issuer Purchases of Equity Securities

 During the fiscal year ended September 30, 2024,
and 2023 the Company did not repurchase any shares of its Common Stock.

 Item 6. [Reserved]

 Item 7. Management's Discussion and Analysis
of Financial Condition and Results of Operations

 We are a development stage corporation with limited
operations and no revenues from our business operations. Our auditors have issued a going concern opinion. This means that our auditors
believe there is substantial doubt that we can continue as an on-going business for the next twelve months. We do not anticipate that
we will generate significant revenues until we have raised the funds necessary to conduct a marketing program.

 PLAN OF OPERATION

 FISCAL YEAR ENDED SEPTEMBER 30, 2024
COMPARED TO FISCAL YEAR ENDED SEPTEMBER 30, 2024.

 Our net loss for the fiscal year ended
September 30, 2024 was $58,213 compared to a net loss of $37,138 during the fiscal year ended September 30, 2023. In September 30,
2024 and September 30, 2023 the Company had not generated any revenue respectively.

 All revenue generated by the Company was done
so by operations that have been discontinued.

 Expenses incurred were $54,707 during fiscal
year ended September 30, 2024 compared to $37,593 during fiscal year ended September 30, 2023. Expenses increased due to the
Company's operational activities.

 The number of shares outstanding was 5,920,000
for the fiscal year ended September 30, 2024 and September 30, 2024.

 LIQUIDITY AND CAPITAL RESOURCES

 FISCAL YEAR ENDED September 30, 2024 and
2023.

 As of September 30, 2024, our total assets were
$159.

 As of September 30, 2023, our total assets were
$159.

 Cash Flows from Operating Activities

 We have not generated positive cash flows
from operating activities. For the fiscal year ended September 30, 2024, net cash flows used in operating activities was $83,585.
For the fiscal year ended September 30, 2023, net cash flows used in operating activities was $25,739.

 Cash Flows from Investing Activities

 We have not generated cash flows from investing
activities for the fiscal years ended September 30, 2024, and 2023.

 Cash Flows from Financing Activities

 We have financed our operations primarily from
either advances from our third party investors or the issuance of equity. For the fiscal year ended September 30, 2024, net cash provided
by financing activities was $83,585. For the fiscal year ended September 30, 2023, net cash provided by financing activities was $25,898.

 OFF-BALANCE SHEET ARRANGEMENTS

 We have no off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources.

 GOING CONCERN

 There is no historical financial information about
us upon which to base an evaluation of our performance. We are in start-up stage operations and have not generated any revenues. We cannot
guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business
enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

 We have no assurance that future financing will
be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or
expand our operations. Equity financing could result in additional dilution to existing shareholders.

 The extent of the impact of the coronavirus ("COVID-19")
outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak
and related advisories and restrictions and the impact of COVID-19 on the overall economy, all of which are highly uncertain and cannot
be predicted. If the overall economy is impacted for an extended period, the Company's future operating results may be materially
adversely affected.

 Critical Accounting Policies

 The discussion and analysis of our financial condition
and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles
generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, and expenses. These estimates and assumptions are affected by management's
application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with
the following aspects of our financial statements is critical to an understanding of our financial statements.

 Use of Estimates

 The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual
results could differ from these good faith estimates and judgments.

 Item 7A. Quantitative and Qualitative Disclosures about Market Risk

 Not applicable to smaller reporting companies.

 Item 8. Financial Statements and Supplementary Data

 The Company's Financial Statements required
by Item 8, together with the reports thereon of the Independent Registered Public Accounting Firm are set forth on pages F-1 through F-9
of this report and are incorporated by reference in this Item 8.

 Item 9. Changes in and Disagreements with Accounting
and Financial Disclosures.

 None.

 Item 9A. Controls and Procedures.

 Disclosure Controls and Procedures

 Disclosure controls and procedures are designed
to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized
and reported, within the time period specified in the SEC's rules and forms, and that such information is accumulated and communicated
to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures. Our management necessarily
applied its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable
assurance regarding management's control objectives.

 Our management, with the participation of our
CEO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered
by this Report. Based upon this evaluation, our CEO concluded that our disclosure controls and procedures were not effective because of
the identification of a material weakness in our internal control over financial reporting which is described below.

 Management's Report on Internal Control
Over Financial Reporting

 Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Rule 13a-15(f). Our internal control
over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the
reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with U.S. GAAP.

 Our internal control over financial reporting
includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with U.S. GAAP and our receipts and expenditures are being made only in accordance
with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.

 Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. All internal control systems, no matter how well designed, have
inherent limitations, including the possibility of human error and the circumvention of overriding controls. Accordingly, even effective
internal control over financial reporting can provide only reasonable assurance with respect to financial statement preparation. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 Our management assessed the effectiveness of our
internal control over financial reporting as of September 30, 2024. In making this assessment, it used the criteria set forth by the Committee
of Sponsoring Organizations of the Tread way Commission ("COSO") in Internal Control-Integrated Framework (2013). Based on
this evaluation, management concluded that that our internal control over financial reporting was not effective as of September 30, 2024.
Our CEO concluded we have a material weakness due to lack of segregation of duties, a limited corporate governance structure, and a lack
of a formal management review process over preparation of financial information. A material weakness is a deficiency, or a combination
of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented or detected on a timely basis.

 Our size has prevented us from being able to employ
sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our system of internal control.
Therefore, while there are some compensating controls in place, it is difficult to ensure effective segregation of accounting and financial
reporting duties. Management reported the following material weaknesses:

 Certain reports that we prepare, and accounting and reporting conclusions reached in connection with the financial statement preparation process are not subjected to a formal review process that includes multiple levels of review and are not submitted timely to the Board of Directors for review or approval; and

 Lack of segregation of duties in certain accounting and financial reporting processes including the initiation, processing, recording and approval of disbursements;

 Our corporate governance responsibilities are performed by the Board of Directors, none of whom are independent under applicable standards; we do not have an audit committee or compensation committee. Our Board of Directors acts primarily by written consent without meetings which results in several of our corporate governance functions not being performed concurrent (or timely) with the underlying transactions, including evaluation of the application of accounting principles and disclosures.

 The Company lacks adequate financial reporting capabilities – Due to the minimal operations and small size of the Company we have not employed individuals that have the necessary accounting knowledge and expertise to ensure accurate financial reporting under US GAAP.

 The Company lacks appropriate information technology controls – As of September 30, 2024, the Company retains copies of all financial data and material agreements; however, there is no formal procedure or evidence of normal backup of the Company's data or off-site storage of data in the event of theft, misplacement, or loss due to unmitigated factors.

 While we strive to segregate duties as much as
practicable, there is an insufficient volume of transactions at this point in time to justify additional full-time staff. We believe that
this is typical in many development stage companies. We may not be able to fully remediate the material weakness until we commence operations
at which time, we would expect to hire more staff. We will continue to monitor and assess the costs and benefits of additional staffing.

 This Annual Report does not include an attestation
report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not
subject to attestation by our registered public accounting firm pursuant to the SEC rules that permit us to provide only management's
report in this Annual Report.

 Changes in Internal Control Over Financial
Reporting

 There were no changes in our internal control
over financial reporting that occurred during the Year ended September 30, 2024, that has materially affected, or is reasonably likely
to materially affect, our internal control over financial reporting.

 Item 9B. Other Information.

 During the quarter ended September 30,
2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as
each term is defined in Item 408(a) of Regulation S-K.

 Item 9C. Disclosures Regarding Foreign Jurisdictions
that Prevent Inspections.

 Not Applicable.

 Item 10. Directors, Executive Officers, and
Corporate Governance.

 The board of directors elects our executive officers
annually. A majority vote of the directors who are in office is required to fill vacancies. Each director is elected for the term of one
year, and until his or her successor is elected and qualified, or until his earlier resignation or removal. The name, address, age and
position of our officers and directors are as follows:

 Name and Address of Executive

 Officer and/or Director

 Age

 Position

 Chen Zu De

 9314 FOREST HILL BLVD, #929, WELLINGTON, FL, 33411

 President, Secretary, Treasurer and Director

 The person named above has held his offices/positions
since the inception of our Company and is expected to hold said offices/positions until the next annual meeting of our stockholders.

 On December 28, 2022, the previous majority shareholder
of Medicale Corp. (the "Company") BorisiAlborovi entered into a stock purchase agreement for the sale of 3,200,000 shares
of Common Stock of the Company (the "Shares") to Magenta Acres, Inc.

 As a result of the acquisition of the Shares,
Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able
to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately,
the direction of our Company.

 On December 28, 2022, the previous sole officer
and director of the Company, BorisiAlborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed
as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 Resume

 Mr Chen Zu De, who was born in 1962 (aged 62),
served as Vice-President of Finance of Zhejiang Rongye Building Materials Co., Ltd from May 2017 to October 2022. He served as project
team manager and project team lead at Anhui Jiayiyang Technology Co. from February 2009 to March 2017. Prior to this appointment, Mr Chen
served in various capacities in technology and construction companies in Zhejiang and Anhui. He attended Zhejiang Lishui University, graduating
in 1988 with a degree in Mathematics and Statistics.

 Committees of the Board

 Our Company currently does not have nominating,
compensation or audit committees or committees performing similar functions, nor does our Company have a written nominating, compensation
or audit committee charter. Our director believes that it is not necessary to have such committees, at this time, because the functions
of such committees can be adequately performed by the sole director.

 Our Company does not have any defined policy or
procedural requirements for shareholders to submit recommendations or nominations for Directors. The sole director believes that, given
the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop
to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the sole
director and we do not have any specific process or procedure for evaluating such nominees. The sole director, will assess all candidates,
whether submitted by management or shareholders, and make recommendations for election or appointment.

 A shareholder who wishes to communicate with our
sole director may do so by directing a written request addressed to our president and director, at the address appearing on the first
page of this Prospectus.

 Corporate Governance

 The Company promotes accountability for adherence
to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable disclosure in reports and documents
that the Company files with the Securities and Exchange Commission (the "SEC") and in other public communications made by
the Company; and strives to be compliant with applicable governmental laws, rules and regulations. The Company has not formally adopted
a written code of business conduct and ethics that governs the Company's employees, officers and directors as the Company is not
required to do so.

 In lieu of an Audit Committee, the Company's
sole director is responsible for reviewing and making recommendations concerning the selection of outside auditors, reviewing the scope,
results and effectiveness of the annual audit of the Company's financial statements and other services provided by the Company's
independent public accountants. The sole director reviews the Company's internal accounting controls, practices and policies.

 Delinquent Section 16(a) Reports

 Our common stock is not registered pursuant to
Section 12 of the Exchange Act of 1934, as amended (the "Exchange Act"). Accordingly, our officers, directors and principal
stockholders are not subject to the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act.

 Code of Business Conduct

 We have not adopted a Code of Business Conduct
within the meaning of Item 406(b) of Regulation S-K.

 Board Committees

 We do not have any Board Committees.

 Item 11. Executive Compensation.

 The table below summarizes the total compensation
earned by each of our named executive Officers ("NEOs") for each of the fiscal years listed.

 SUMMARY COMPENSATION TABLE

 Management Compensation

 The following tables set forth certain information
about compensation paid, earned or accrued for services by our sole officer and director from September 30, 2021 until September 30, 2024:

 Name and

 Principal

 Position

 Years

 Salary

 ($)

 Bonus

 ($)

 Stock

 Awards

 ($)

 Option

 Awards

 ($)

 Non-Equity

 Incentive Plan

 Compensation

 ($)

 Nonqualified

 Deferred

 Compensation

 ($)

 All Other

 Compensation

 ($)

 Total

 ($)

 BorisiAlborovi, President,

 2022

 12,000

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 12,000

 Treasurer and Secretary(Former)

 Chen Zu De, President,

 2023

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 Treasurer and Secretary(Current)

 2024

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 -0-

 Mr. Albrovi is reimbursed for any out-of-pocket
expenses that he incurs on our behalf. In the future, we may approve payment of salaries for officers and directors, but currently, no
such plans have been approved. We also do not currently have any benefits, such as health or life insurance, available to our employees.

 Compensation of Directors

 Directors are permitted to receive fixed fees
and other compensation for their services as directors. The Board of Directors has the authority to fix the compensation of directors.
No amounts have been paid to, or accrued to, our director in such capacity.

 Stock Plan

 We have not adopted a stock plan but may do so
in the future.

 Employment Agreements

 The executive officer is currently not a party
to any employment agreement with us.

 Director Independence

 Our securities are not currently traded on any
public exchange and as such, we are not currently subject to corporate governance standards of listed companies, which require, among
other things, that the majority of the board of directors be independent. We are not currently subject to corporate governance standards
defining the independence of our directors, and we have chosen to define an "independent" director in accordance with the
NASDAQ Global Market's requirements for independent directors.

 Under the NASDAQ rules, our current director does
not qualify as an independent director.

 Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matter.

 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 Directors and Executive Officers

 The following table sets forth the beneficial
ownership (and the percentages of outstanding shares represented by such beneficial ownership) as of September 30, 2024, of (i) each director,
(ii) the current NEOs named in the "Summary Compensation Table" contained in this Form 10-K and (iii) all current directors
and executive officers as a group. Except as otherwise indicated, we believe that the beneficial owners of the common stock listed below,
based on information provided by such owners, have sole investment and voting power with respect to such shares, subject to community
property laws where applicable. Persons, who have the power to vote or dispose of common stock of the Company, either alone or jointly
with others, are deemed to be beneficial owners of such common stock.

 Chen Zu De, President, CEO, Treasurer, Secretary and Chairman of the Board.

 3,200,000 shares

 Certain Stockholders

 The following table sets forth certain information
with respect to each person known by us to be the beneficial owner of five percent or more of either class of the Company's outstanding
common stock. The content of this table is based upon the most current information contained in Schedules 13D or 13G filings with the
SEC, unless more recent information was obtained.

 Chen Zu De, President, CEO, Treasurer, Secretary and Chairman of the Board.

 54%

 This percentage is calculated based on the outstanding
shares of 5,920,000 as of September 30, 2024.

 Item 13. Certain Relationships and Related
Transactions, and Director Independence.

 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 The following table sets forth certain information
concerning the number of shares of our common stock owned beneficially as of September 30, 2024by: (i) each person (including any group)
known to us to own more than five percent (5%) of any class of our voting securities, (ii) our director, and or (iii) our officer. Unless
otherwise indicated, the stockholder listed possesses sole voting and investment power with respect to the shares shown.

 Title of Class

 Name and Address

 of

 Beneficial Owner

 Amount and

 Nature of

 Beneficial

 Ownership

 Percentage

 Of Common Stock

 Common

 Chen Zu De

 3,200,000

 54%

 Common

 All Officers and Directors as a Group (1 person)

 3,200,000

 54%

 Future Sales by Existing Shareholders

 A total of 3,200,000 common shares at $0.0001
per share have been issued to our sole stockholder. They are restricted securities, as that term is defined in Rule 144 of the Rules and
Regulations of the SEC promulgated under the Act. Under Rule 144, such shares can be publicly sold, subject to volume restrictions and
certain restrictions on the manner of sale, commencing six months after their acquisition.

 Any sale of shares held by the existing stockholder
(after applicable restrictions expire) and/or the sale of shares purchased in this offering (which would be immediately resalable after
the offering), may have a depressive effect on the price of our common stock in any market that may develop, of which there can be no
assurance.

 Item 14. Principal Accountant Fees and Services.

 FEES TO THE COMPANY'S AUDITORS

 Set forth below is a summary of certain fees paid
to our independent auditGreenGrowth CPAs(formallyGries & Associates, LLC) and Victor Mokuolu. CPA. PLLC, Independent registered public
accountants for services for the fiscal years 2024and 2023.

 Fee Category

 Fiscal Year
 2024

 Fiscal Year
 2023

 Audit Fees

 $
 24,958

 $
 6,000

 Tax Fees

 –

 –

 All Other Fees

 –

 –

 Total

 $
 24,958

 $
 6,000

 Audit Fees

 Audit fees were for professional services rendered
in connection with the audit of our annual financial statements set forth in our Annual Reports on Form 10-K, the review of our quarterly
financial statements set forth in our Quarterly Reports on Form 10-Q and consents for other SEC filings.

 Audit-Related Fees

 Audit-related fees consist of fees billed for
professional services for consultation on accounting matters.

 Approval of Services Provided by Independent
Registered Public Accounting Firm

 The Board of Directors has considered whether
the services provided under other non-audit services are compatible with maintaining the auditor's independence and has determined
that such services are compatible. The Board of Directors has adopted policies and procedures for pre-approving all non-audit work performed
by the external auditors. The Board of Directors will annually pre-approve services in specified accounting areas. The Board of Directors
also annually approves the budget for the annual generally accepted accounting principles (GAAP) audit.

 Item 15. Exhibit and Financial Statement Schedules.

 (a)(1) Financial Statements

 The following documents are filed as
part of this report:

 The Financial Statements of Medicale
Corp. at September 30, 2024and 2023, and for each of the two fiscal years in the period ended September 30, 2024, together with the reports
of the Independent Registered Public Accounting Firms, are set forth on pages F-1 through F-11 of this Report.

 (2) Not applicable.

 (3) Exhibits

 31.1

 Certification of the Chief Executive/Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

 32.1

 Certification of the Chief Executive/Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 Item 16. Form 10-K Summary.

 None.

 SIGNATURES

 Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on January 14, 2025.

 By:

 /s/ Chen Zu De

 Chen Zu De

 President and Chief Executive Officer

 Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated
on January 14, 2025.

 Signature

 Title

 /s/ Chen Zu De

 President, Chief Executive Officer, Treasurer, Secretary,

 Chen Zu De

 and Director (Principal Executive Officer and Principal Accounting Officer)

 INDEX TO FINANCIAL STATEMENTS

 Report of Independent Registered Accounting Firm (ID 6771)

 Balance Sheets as of September 30, 2024 and 2023

 Statements of Operations for the Year ended September 30, 2024 and for the Year ended September 30, 2023

 Statements of Stockholders' Deficit for the Year ended September 30, 2024 and for the Year ended September 30, 2023

 Statements of Cash Flows for the Year ended September 30, 2024 and for the Year ended September 30, 2023

 Notes to the Financial Statements

 F- 1

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

 VICTOR MOKUOLU, CPA PLLC

 Accounting
 | Advisory | Assurance & Audit | Tax

 To the Board of Directors and Stockholders

 Medicale Corp.

 Opinion on the Financial Statements

 We have audited the accompanying balance sheet
of Medicale Corp. (the Company) as of September 30, 2024, and the related statements of operations, stockholders' deficit, and cash
flows for the year ended September 30, 2024, and the related notes (collectively referred to as the financial statements). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024, and
the results of its operations and its cash flows for the year ended September 30, 2024, in conformity with accounting principles generally
accepted in the United States of America.

 Substantial doubt about the Company's
ability to continue as a Going concern

 The accompanying financial statements have been
prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered
recurring losses and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over
an extended period of time. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 www.vmcpafirm.com
 | Ph: 713.588.6622 | Fax: 1.833.694.1494 | ask@vmcpafirm.com

 F- 2

 VICTOR MOKUOLU, CPA PLLC

 Accounting
 | Advisory | Assurance & Audit | Tax

 Other Matters

 The audit of the accompanying balance sheet of
Medicale Corp. as of September 30, 2023, and the related statements of operations, stockholders' deficit, and cash flows for the
year ended September 30, 2023, and the related notes (collectively referred to as the financial statements) was performed by another Independent
Registered Public Accounting Firm, Greengrowth CPAs.

 Victor Mokuolu, CPA PLLC

 We have served as the Company's auditor since 2024.

 Houston, Texas

 January 14, 2025

 PCAOB ID: 6771

 www.vmcpafirm.com
 | Ph: 713.588.6622 | Fax: 1.833.694.1494 | ask@vmcpafirm.com

 F- 3

 REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

 Board of Directors and Shareholders

 Medicale Corp.

 Opinion on the Financial Statements

 We have audited the accompanying balance sheets of Medicale Corp.
as of September 30, 2023, and the related statements of operations, stockholders' deficit and cash flows for the year ended September
30, 2023, and the related notes to the financial statements. In our opinion, the financial statements present fairly, in all material
respects, the financial position of Medicale Corp. as of September 30, 2023, and the results of its operations and its cash flows for
the period then ended, in conformity with accounting principles generally accepted in the United States of America.

 Going Concern

 The accompanying financial statements have been prepared assuming that
the entity will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses
from operations and has not yet generated any revenues. This raises substantial doubt about the Company's ability to continue as
a going concern. Management's plans in regard to these matters are also described in Note 2 to the financial statements. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility of the entity's
management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting
firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent
with respect to Medicale Corp. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.

 We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. Medicale Corp. is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial
reporting. Accordingly, we express no such opinion.

 Our audits included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 GreenGrowth CPAs

 December 29, 2023

 We served as the Company's auditor in 2023

 Los Angeles, California

 PCAOB ID Number 6580

 F- 4

 BALANCE SHEETS

 September 30,
 2024

 September 30,
 2023

 ASSETS

 Current Assets

 Cash

 $

 $

 Total current assets

 Total Assets

 $

 $

 LIABILITIES AND STOCKHOLDERS' DEFICIT

 Current Liabilities

 Related party advances

 $
 –

 $
 20,480

 Accounts payable and accrued expenses

 3,507

 8,399

 Current liabilities from discontinued operations

 12,000

 12,000

 Total Current Liabilities

 15,507

 40,879

 Long term Liabilities

 Non-Current Convertible Note Payable

 83,585

 –

 Total Long-term Liabilities

 83,585

 –

 Total Liabilities

 99,092

 40,879

 Stockholders' Deficit

 Common stock, $ 0.0001 par value, 75,000,000 shares authorized; 5,920,000 shares issued and outstanding

 Additional paid-in-capital

 76,320

 76,320

 Accumulated deficit

 ( 175,845
)

 ( 117,632
)

 Total Stockholders' Deficit

 ( 98,933
)

 ( 40,720
)

 Total Liabilities and Stockholders' Deficit

 $

 $

 See accompanying notes, which are an integral part
of these financial statements.

 F- 5

 STATEMENTS OF OPERATIONS

 For the year ended
 September 30, 2024

 For the year ended
 September 30, 2023

 OPERATING EXPENSES

 General and Administrative Expenses

 $
 54,707

 $
 37,593

 TOTAL OPERATING EXPENSES

 54,707

 37,593

 NET LOSS FROM OPERATIONS

 ( 54,707
)

 ( 37,593
)

 OTHER EXPENSES

 Interest Expense

 3,506

 –

 TOTAL OTHER EXPENSES

 3,506

 –

 LOSS BEFORE TAXES

)

 ( 37,593
)

 PROVISION FOR INCOME TAXES

 –

 –

 Loss from continuing operations

)

 ( 37,593
)

 Income(loss) from discontinued operations

 –

 NET LOSS

 $
)

 $
 ( 37,138
)

 NET LOSS PER SHARE; BASIC AND DILUTED

 $
 ( 0.01
)

 $
 ( 0.01
)

 WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING; BASIC AND DILUTED

 See accompanying notes, which are an integral part
of these financial statements.

 F- 6

 STATEMENT OF STOCKHOLDERS' DEFICIT

 For
the Years Ended September 30, 2024 and 2023

 Common Stock

 Additional
 Paid-in

 Accumulated

 Total
 Stockholders'

 Shares

 Amount

 Capital

 Deficit

 Deficit

 Balance, September 30, 2022

 $

 $
 25,128

 $
 ( 80,494
)

 $
 ( 54,774
)

 Debt forgiveness by related party

 –

 –

 51,192

 –

 51,192

 Net loss for the period ended September 30, 2023

 –

 –

 –

 ( 37,138
)

 ( 37,138
)

 Balance, September 30, 2023

 $

 $
 76,320

 $
 ( 117,632
)

 $
 ( 40,720
)

 Net loss for the period ended September 30, 2023

 –

 –

 –

)

)

 Balance, September 30, 2024

 $

 $
 76,320

 $
 ( 175,845
)

 $
 ( 98,933
)

 See accompanying notes, which are an integral part
of these financial statements

 F- 7

 STATEMENTS OF CASH FLOWS

 For the year ended
 September 30,
 2024

 For the year ended
 September 30,
 2023

 CASH FLOWS FROM OPERATING ACTIVITIES

 Net loss for the period

 $
)

 $
 ( 37,593
)

 Net income (loss) for the period from discontinued operation

 –

 Changes in operating assets and liabilities:

 Accounts payable and accrued expenses

 ( 4,892
)

 11,399

 Related party short term advance

 ( 20,480
)

 –

 CASH FLOWS USED IN OPERATING ACTIVITIES

 ( 83,585
)

 ( 25,739
)

 CASH FLOWS FROM INVESTING ACTIVITIES

 –

 –

 CASH FLOWS FROM FINANCING ACTIVITIES

 Proceeds from Convertible Note

 83,585

 –

 Proceeds from related party short term advances

 –

 25,898

 CASH FLOWS PROVIDED BY FINANCING ACTIVITIES

 83,585

 25,898

 NET INCREASE IN CASH

 –

 Cash and equivalents at beginning of the period

 –

 Cash and equivalents at end of the period

 $

 $

 Supplemental cash flow information:

 Cash paid for:

 Interest

 $
 –

 $
 –

 Taxes

 $
 –

 $
 –

 Non-cash investing and financing activities:

 Debt forgiveness by related party

 $
 –

 $
 51,192

 See accompanying notes, which are an integral part
of these financial statements.

 F- 8

 NOTES TO THE FINANCIAL STATEMENTS

 FOR THE YEARS ENDED SEPTEMBER 30, 2024 and
2023

 Note 1 – ORGANIZATION AND NATURE
OF BUSINESS

 MEDICALE CORP ("the Company,", "we,"
"us" or "our") was incorporated in the State of Nevada on August 17, 2020. We plan to offer consulting services
and distribution of the dietary supplements. A dietary supplement is a manufactured product intended
to supplement the diet when taken by mouth as a pill, capsule, tablet, or liquid. A supplement can provide nutrients either
extracted from food sources or synthetic, individually or in combination, in order to increase the quantity of their consumption.

 On December 28, 2022, the previous majority
shareholder of Medicale Corp. (the "Company") Borisi Alborovi entered into a stock purchase agreement for the sale of
3,200,000 shares of Common Stock of the Company (the "Shares") to Magenta Acres, Inc.

 As a result of the acquisition of the Shares,
Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able
to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately,
the direction of our Company.

 On December 28, 2022, the previous sole
officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De
was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 As of the date of this report, the Company had
not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital,
and continuing the Company's public reporting.

 Our principal place of business is located 9314
Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director. Our
telephone number is (407) 245-7339.

 Note 2 – GOING CONCERN

 The accompanying financial statements have been
prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), which contemplate
continuation of the Company as a going concern. The Company has an accumulated deficit of $ 175,845 and a working capital deficit of 15,348
as of September 30, 2024. The Company currently has losses and has not completed its efforts to establish a stabilized source of revenues
sufficient to cover operating costs over an extended period of time. Therefore, there is substantial doubt about the Company's ability
to continue as a going concern. Management anticipates that the Company will be dependent, for the near future, on additional investment
capital to fund operating expenses. The Company intends to position itself so that it will be able to raise additional funds through the
capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of
its endeavors or become financially viable and continue as a going concern.

 F- 9

 Note 3 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES

 Basis of presentation

 The accompanying financial statements have been
prepared in accordance with generally accepted accounting principles in the United States of America. The Company's year-end is
September 30.

 Use of Estimates

 The preparation of financial statements in conformity
with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the
reporting period. Actual results could differ from those estimates.

 Cash equivalents

 The Company considers all highly liquid
investments with maturities of three months or less at the time of purchase to be cash equivalents. The cash equivalents as of
September 30, 2024 and 2023 were $ 159 and $ 159, respectively.

 Fair Value of Financial Instruments

 FASB ASC Topic 820, "Fair Value Measurement," defines
fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to
recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair
values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure
fair value.

 The three levels are defined as follows:

 Level 1:

 defined as observable inputs such as quoted prices in active markets;

 Level 2:

 defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 Level 3:

 defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 Due to its short-term nature, the carrying value
of cash, director loans and issuance of common stock approximated fair value at September 30, 2024.

 Income Taxes

 The Company is a C Corporation under the Internal
Revenue Code and a similar section of the state code.

 All income tax amounts reflect the use of the
liability method under accounting for income taxes. Income taxes are provided for the tax effects of transactions reported in the financial
statements and consist of taxes currently due plus deferred taxes arising primarily from differences between financial and tax reporting
purposes. Current year expense represents the amount of income taxes paid, payable or refundable for the period.

 F- 10

 Deferred income taxes, net of appropriate valuation
allowances, are determined using the tax rates expected to be in effect when the taxes are actually paid. Valuation allowances are recorded
against deferred tax assets when it is more likely than not that such assets will not be realized. When an uncertain tax position meets
the more likely than not recognition threshold, the position is measured to determine the amount of benefit or expense to recognize in
the financial statements.

 The Company's income tax returns are
subject to review and examination by federal, state and local governmental authorities. As of September 30, 2024, our September 30,
2023 tax return was open to examination with federal, state and local governmental authorities. To the extent penalties and interest
are incurred through an examination, they would be included as part of operations in the statement of operations.

 Long-Lived Assets – Intangible Assets

 We account for our intangible assets in accordance
with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal
of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair
value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic
350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period
to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life
is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs
of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred.

 Impairment of Long-Lived Assets

 We continually monitor events and changes in
circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in
circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of
such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than
the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the
fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to
sell. During the year ended September 30, 2024 we recognized $ 0 of impairment expense.

 Basic Income (Loss) Per Share

 The Company computes income (loss) per share
in accordance with FASB ASC 260 "Earnings per Share". Basic loss per share is computed by dividing net income (loss)
available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income
(loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share
excludes all potential common shares if their effect is anti-dilutive. As of September 30, 2024 there were no potentially dilutive
debt or equity instruments issued or outstanding.

 Comprehensive Income

 Comprehensive income is defined as all
changes in stockholders' equity, exclusive of transactions with owners, such as capital investments. Comprehensive income
includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation
adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. As of September
30, 2024 were no differences between our comprehensive loss and net loss.

 F- 11

 Recent Accounting Pronouncements

 We have reviewed all the recently issued, but
not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

 Risks and Uncertainties

 The ultimate impact of the COVID-19 pandemic on
the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with
confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19
pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an
extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot
be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results
of operations.

 Management expects that its business will be impacted
to some degree, but the significance of the impact of the COVID-19 outbreak on the Company's business and the duration for which
it may have an impact cannot be determined at this time.

 Note 4– COMMON STOCK

 The Company has 75,000,000, $ 0.0001 par value shares of voting common
stock authorized.

 All shares of common stock have voting rights and are identical. All
holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock
held by such stockholder.

 On December 28, 2022, Borisi Alborovi, the previous majority
shareholder of Medicale Corp. (the "Company"), entered into a stock purchase agreement for the sale of 3,200,000 shares
of Common Stock of the Company (the "Shares") to Magenta Acres, Inc.

 As of September 30, 2024 the company had 5,920,000 shares issued and
outstanding.

 As of September 30, 2023 the company had 5,920,000 shares issued and
outstanding.

 Voting Common Stock

 All shares of common stock have voting rights
and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for
each share of the capital stock held by such stockholder.

 Non-voting Common Stock

 All of the other terms of the Non-Voting Common
Stock shall be identical to the Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock,
as explained in the Company's Bylaws.

 F- 12

 Note 5 – COMMITMENTS AND CONTINGENCIES

 In the normal course of business, the Company
may become a party to litigation matters involving claims against it. At September 30, 2024, there are no current matters that would have
a material effect on the Company's financial position or results of operations.

 Note 6– RELATED PARTY TRANSACTIONS

 The sole officer and director, Borisi
Alborovi, was the only related party with whom the Company had transactions with during the period from inception on August 17, 2020
through December 31, 2022.

 On December 28, 2022, the previous sole
officer and director, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as
Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company.

 As a result of the acquisition of the Shares
on December 28, 2022, the previous majority shareholder of Medicale Corp. (the "Company") Borisi Alborovi forgive the
debt that due to him, with the amount of $ 51,192.

 As of December 31, 2023 and September 30, 2023,
the Company owed Mr. Alborovi $ nil and $ nil respectively, for operating expenses on behalf of the Company. The amounts due to
the related party are unsecured and non-interest bearing with no set terms of repayment.

 As of September 30, 2024 and September 30, 2023,
the Company owed Chen Zu De $ nil and $ nil respectively, for operating expenses on behalf of the Company. The amounts due to
the related party are unsecured and non-interest bearing with no set terms of repayment.

 Note
7– CONVERTIBLE NOTE PAYABLE

 On
December 31, 2023, the company entered into a Convertible Note agreement with a third party at $ 48,186.
The note bears a 8 %
interest rate per year and matures on December 31, 2029. The note can be converted to the Company's common stock at $0.01 per
share. As of September 30, 2024, the accrued interest is $ 2,894.

 On
March 31, 2024, the company entered into a Convertible Note agreement with a third party at $ 10,602.
The note bears a 8 %
interest rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.01 per
share. As of September 30, 2024, the accrued interest is $ 425.

 On
June 30, 2024, the company entered into a Convertible Note agreement with a third party at $ 9,288. The note bears a 8 % interest
rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.01 per share. As of
September 30, 2024, the accrued interest is $ 187.

 On
September 30, 2024, the company entered into a Convertible Note agreement with a third party at $ 15,509
The note bears a 8 %
interest rate per year and matures on March 31, 2030. The note can be converted to the Company's common stock at $0.01 per
share. As of September 30, 2024, the accrued interest is $ nil.

 F- 13

 Note 8 – INCOME TAXES

 Our Company has not
filed any federal income tax returns and we are currently not subject to state income tax filing requirements. As of September 30,
2024, we have net operating loss carryforwards, on a book basis, of $ 164,051 which may be available to reduce various future years'
federal taxable income. Future tax benefits which may result from these losses have not been recognized in these financial
statements, as their realization is determined not likely to occur and accordingly, we have recorded a valuation allowance for the
deferred tax asset relating to the net operating loss carry forwards.

 The following table presents
the current income tax provision for federal and state income taxes for the years ended September 30, 2024 and 2023:

 Schedule of income tax provision

 2024

 2023

 Current tax provisions:

 Federal

 $
 –

 $
 –

 State

 –

 –

 Total provision for income taxes

 $
 –

 $
 –

 Reconciliations
of the U.S. federal statutory rate to the actual tax rate for the years ended September 30, 2024 and 2023:

 Schedule of tax rates

 2024

 2023

 US federal statutory income tax rate

 21.0 %

 21.0 %

 Increase in valuation reserve

 - 21.0 %

 - 21.0 %

 Total provision for income taxes

 0.0 %

 0.0 %

 The
components of our deferred tax assets as of September 30, 2024 and 2023 consisted of the following:

 Schedule of deferred tax assets

 2024

 2023

 Net operating loss carry forwards

 $

 36,928

 $

 24,703

 Less: valuation allowance

 ( 36,928

)

 ( 24,703

)

 Net deferred tax assets

 $

 –

 $

 –

 During
the year ended September 30, 2024, the valuation reserve increased $ 12,225 compared to an increase of $ 7,803 during the year
ended September 30, 2023. In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not
that our Company will not realize some portion or all of the deferred tax assets. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers
the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment.
As a result, management determined, as of September 30, 2024, that it was more likely than not the deferred tax assets would not be realized.

 As
noted above, we have not filed any federal tax returns, but we plan on bringing our tax filings current as soon as is practical.

 Note 9– SUBSEQUENT EVENTS

 In accordance with SFAS 165 (ASC 855-10) the
Company has analyzed its operations subsequent to September 30, 2024 to the date these financial statements were issued and has
determined that it does not have any material subsequent events to disclose in these financial statements.

 F- 14